MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Phenotypic Heterogeneity and Variability of Nigrostriatal Dopaminergic Function in a Dopa-Responsive Dystonia

J.J. Lin (Nantou, Taiwan)

Meeting: 2018 International Congress

Abstract Number: 702

Keywords: Dopa-responsive dystonia(DRD), Parkinsonism, Single-photon emission computed tomography(SPECT)

Session Information

Date: Sunday, October 7, 2018

Session Title: Dystonia

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: To evaluate presynaptic nigrostriatal dopaminergic function in a Dopa-responsive dystonia (DRD) family with guanosine triphosphate cyclohydrolase 1 (GCH-1) mutation.

Background: Mutation of GCH-1 located on chromosome 14q22.1-22.2, is the most common and best characterized condition that manifests as DRD. Since the gene products of GCH-1 are related to tyrosine hydroxylation, impairment of dopamine production in the nigral cell seems to be responsible for DRD. However, results of the functional imaging using 18F-fluorodopa positron emission tomography or single photon emission computed tomography (SPECT) of the dopamine transporter (DAT) was still controversial.

Methods: Three of five members of the DRD family were found to have a heterozygous T241C mutation in exon 1 of GCH-1. We studied the presynaptic nigrostriatal dopaminergic function using 99mTc-TRODAT-1 (TRODAT) SPECT imaging in those three members. We further analyze the correlation between the phenotypic presentation of DRD and the nigrostriatal dopaminergic function.

Results: Clinically, there was presentation of clinical Heterogeneity in the DRD family; one was a classic DRD (proband), one presented with parkinsonism which was distinguishable from typical PD, and the other one was an asymptomatic gene carrier. The index patient was a 10-year-old girl with classic DRD and normal presynaptic nigrostriatal dopaminergic function. However, her grandmother, a 79-year-old woman, presented with slowly progressive Parkinson’s disease (PD) and excellent response to dopaminergic therapy for 21 years. Her brain TRODAT SPECT imaging revealed a markedly and asymmetrically reduced uptake of dopamine transporter at the bilateral striatum. Her father, a 54-year-old man, was an asymptomatic gene carrier and his brain TRODAT SPECT imaging revealed asymmetrically reduced nigrostriatal dopaminergic transmission in the bilateral striatum.

Conclusions: We conclude variability of presynaptic nigrostriatal dopaminergic function in patients with DRD is related to their clinical heterogeneity.

References: 1. Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, et al (2014) Parkinson’s disease in GTP cyclohydolase 1 mutation carrier. Brain 137:2480-2492. 2. Wijemannes S, Jankovic J (2015) Dopa-responsive dystonia- clinical and genetic heterogeneity. Nat Rev Neurol 7:414-424.

To cite this abstract in AMA style:

J.J. Lin. Phenotypic Heterogeneity and Variability of Nigrostriatal Dopaminergic Function in a Dopa-Responsive Dystonia [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/phenotypic-heterogeneity-and-variability-of-nigrostriatal-dopaminergic-function-in-a-dopa-responsive-dystonia/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/phenotypic-heterogeneity-and-variability-of-nigrostriatal-dopaminergic-function-in-a-dopa-responsive-dystonia/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley